OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

Neutralizing intratumoral pH may help improve responses to immunotherapy and improve outcomes with current targeted therapies, according to a study published March 15, 2016, in the journal Cancer Research.

A research team at University of California, Merced has identified a drug that could be effective in targeting melanoma cells.

A 90-year-old woman presents with a lesion in the right forearm. After further assessment, a biopsy is performed. What is your diagnosis?

PRAME mRNA is a biomarker of metastasis risk for patients with class 1 uveal melanoma, according to authors of a retrospective study.

The combination of TriMixDC-MEL and ipilimumab produced durable tumor responses in patients with pretreated advanced melanoma, according to a phase II study.

In light of the recent announcement by Vice President Joe Biden to infuse the US cancer research program with $1 billion, a so-called “Moon Shot” program, we are speaking today with Giulio Draetta, a clinician and cancer researcher at MD Anderson Cancer Center at the University of Texas in Houston, who leads that center’s Moon Shots program.

The PD-1‒targeting drug nivolumab combined with stereotactic radiation may work synergistically and help improve overall survival while resulting in minimal neurotoxicity in brain metastatic melanoma patients.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.